ANKRD11 Identified as Key Immune Brake in Chronic Hepatitis B and Cancer Treatment

Researchers have identified a specific protein that reduces the activity of immune cells, limiting the body’s ability to fight chronic hepatitis B virus and cancer, according to a study published on September 11, 2026, in Nature Immunology.

The Discovery of ANKRD11 in Immune Response Regulation

A collaborative research team led by Prof. Zhou Xuyu at the Institute of Microbiology of the Chinese Academy of Sciences, alongside researchers from Beijing Ditan Hospital and Capital Medical University, discovered that a protein called ANKRD11 reduces the activity of CD8+ T cells over time. According to the research findings, chronic hepatitis B virus infects approximately 296 million people worldwide and ranks as a leading cause of severe liver diseases, including cirrhosis and liver cancer. The human immune system often struggles to control chronic hepatitis B because CD8+ T cells, which normally target and destroy infected cells, lose their strength and fail to multiply effectively within the unique and immunosuppressive environment of the liver.

To uncover the genetic drivers behind this immune exhaustion, the scientists utilized advanced genetic tools to look across the whole genome for genes regulating T-cell responses during chronic infection. Out of numerous candidates, the team focused on Ankrd11 because of its novel role and strong regulatory influence on gene transcription within immune cells. Previous work by the research group established a specialized mouse model mimicking human hepatitis B infection, providing the baseline necessary to target specific immune response regulators.

Mechanisms of T-Cell Enhancement Through Gene Deletion

When the research team removed the Ankrd11 gene from T cells in mice, the genetic modification did not disrupt normal cell development but substantially boosted the cells’ infection-fighting capabilities. According to the study data, these modified T cells produced more important immune molecules and exhibited an enhanced capacity to attack both infected cells and tumors. Mechanistically, the scientists determined that ANKRD11 operates by blocking the AP-1 signaling pathway, which is normally required for T cells to successfully combat pathogens and malignancies. Without ANKRD11 acting as a brake, genes responsible for proper T-cell function remain activated, allowing the cells to resist signals that typically induce immune exhaustion.

Testing across multiple disease models confirmed the therapeutic potential of this genetic targeting. In murine models of hepatitis B, deleting Ankrd11 from T cells drove increased immune cell activity inside the liver, facilitated viral clearance, and yielded improved disease outcomes. Furthermore, in separate virus and cancer models, T cells lacking Ankrd11 successfully fought viral loads and shrank tumors even in scenarios where conventional treatments had previously failed.

Implications for Future Treatments in Chronic Infection and Oncology

The findings demonstrate that ANKRD11 serves as a critical negative regulator suppressing the immune system’s efficacy against persistent viral infections and oncological diseases. The research team observed that combining the targeted inhibition of ANKRD11 with existing therapeutic approaches significantly strengthened overall treatment efficacy. By identifying this molecular brake, the study opens new avenues for developing novel interventions for chronic hepatitis B and cancer designed to reactivate the body’s native immune response when current therapies prove insufficient.